Custom strains for recombinant protein production

Genetically modified E. coli strains with ompT and lon deletions, along with manA mutations, address protease degradation and mucoid phenotypes, enhancing recombinant protein yield and purification efficiency.

JP2024540917AInactive Publication Date: 2024-11-06MODERNATX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523498
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2022-10-17
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Escherichia coli (E. coli) strains used for recombinant protein expression face challenges due to proteases like OmpT and Lon, which degrade proteins, and mucoid phenotypes that hinder purification and fermentation processes.

Method used

Genetically modified E. coli strains with mutations or deletions in ompT, lon, and genes related to exopolysaccharide synthesis (e.g., manA) are developed to reduce protease activity and mucoid phenotypes, enhancing recombinant protein yield and purification efficiency.

Benefits of technology

The modified strains significantly improve recombinant protein yield and purification by minimizing protease degradation and mucoid-related issues, enabling high-purity protein production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540917000001_ABST
    Figure 2024540917000001_ABST
Patent Text Reader

Abstract

Described herein are genetically modified microorganisms that are free of a mucoid phenotype and have reduced protease activity for expression of recombinant proteins, as well as methods of making and using the same.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit under 35 U.S.C. §119(e) of the earlier filing dates of U.S. Provisional Application No. 63 / 256,690, filed October 18, 2021, and U.S. Provisional Application No. 63 / 304,195, filed January 28, 2022, the contents of which are incorporated by reference in their entireties.

[0002] Reference to Electronic Sequence Listing The contents of the electronic sequence listing (M137870169WO00-SEQ-NTJ.xml; size: 122,328 bytes; and creation date: October 14, 2022) are incorporated herein by reference in their entirety. [Background technology]

[0003] Escherichia coli (E. coli) has a long history in biotechnology and pharmaceutical development and has been used for many years as a host for plasmid DNA production. There are various reasons for this, among them the simplicity of E. coli's genes (e.g., a low gene count of approximately 4,400), growth rate, safety, proven track record as a host for foreign DNA, and ease of maintenance. Also, due to its long history of use, E. coli is an organism that has been manipulated in a variety of ways and is well-characterized. For example, several different strains have been constructed for various purposes including cloning, plasmid DNA production, and protein expression. Most commonly, E. coli K12 derivatives used as DH5α, JM108, DH10β, etc. are used for cloning and production of plasmid DNA because they carry certain genomic mutations that are desirable for cloning purposes. These are primarily those that inactivate genes that code for nucleases, recombinases, and other enzymes that reduce the DNA stability, purity, and cloning efficiency of the strain.

[0004] E. coli is also commonly used for recombinant protein expression due to its history as a host bacterium for plasmid cloning and production. However, the E. coli genome encodes several proteases, such as OmpT and Lon, that can cleave proteins expressed by the bacteria, especially mutant or foreign proteins. The presence of these proteases reduces the amount of recombinant protein that can be successfully purified from a given E. coli cell. Furthermore, some protease-deficient variants of E. coli exhibit a mucoid phenotype that interferes with genetic manipulation of the bacteria, mixing of cells and maintaining an aerobic environment during fermentation, and separation of bacterial cells from the culture medium. Summary of the Invention

[0005] Described herein are bacterial strains and vectors engineered for plasmid DNA production, enhanced recombinant protein expression, and improved protein yield. Bacterial proteases such as OmpT and Lon cleave proteins, particularly mutant and foreign proteins, limiting the yield of recombinant proteins expressed in bacterial cells. Many commonly used bacterial strains for recombinant protein expression, such as Escherichia coli BL21 cells, have been modified to delete the ompT gene, but E. coli B strains such as BL21 are believed to naturally lack Lon protease activity due to one or more mutations in the promoter of the lon gene. However, complete deletion of the lon gene from the bacterial chromosome further improved protein yield, but resulted in a mucoid phenotype of the bacterial strain, suggesting that the lon gene is still expressed in E. coli B strains. This mucoid phenotype is due to the accumulation of excess polysaccharides in the absence of Lon protease activity, which prevents efficient pelleting of the bacteria and subsequent purification of the recombinant protein. This mucoid phenotype was not observed in strains lacking manA, which catalyzes the first step in GDP-mannose synthesis and is required for the production of mannose-containing polysaccharides. Thus, bacterial strains lacking ompT, lon, and one or more genes required for the synthesis of exopolysaccharides (e.g., manA) produce greater amounts of recombinant protein than unmodified bacterial strains.

[0006] Thus, some aspects of the disclosure relate to a genetically modified microorganism comprising a genome in which the ompT and lon genes are mutated, disabled, or deleted. In some embodiments, the microorganism does not express a functional form of one or more proteins selected from the group consisting of G6PI, ManA, ManB, ManC, Gmd, Fcl, and Kdul. In some embodiments, the genome comprises a mutation in a gene selected from the group consisting of pgi, manA, manB, manC, gmd, fcl, and kdul. In some embodiments, the genome comprises a mutation in a promoter operably linked to a gene selected from the group consisting of pgi, manA, manB, manC, gmd, fcl, and kdul. In some embodiments, the genome does not comprise a nucleic acid sequence encoding a carbohydrate metabolism protein selected from the group consisting of G6PI, ManA, ManB, ManC, Gmd, Fcl, and Kdul.

[0007] In some embodiments, the microorganism does not express functional ManA. In some embodiments, the genome comprises a mutation in the manA gene or a promoter operably linked to the manA gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding ManA.

[0008] In some embodiments, the genome comprises i) a first nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:23, and ii) a second nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25. In some embodiments, the genome further comprises a third nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:24. In some embodiments, the microorganism does not exhibit a mucoid phenotype. In some embodiments, the genetically modified microorganism is unable to synthesize mannose. In some embodiments, the genetically modified microorganism is unable to synthesize fucose.

[0009] In some embodiments, the genome does not comprise a nucleic acid sequence encoding endA, the genome does not comprise a nucleic acid sequence encoding recA, and the EcoK1 restriction system is inactivated. In some embodiments, the genotype of the microorganism is ΔendA ΔrecA Δ(mrr-hsdRMS-symE-mcrBC) ΔompT ΔmanA Δlon. In some embodiments, the microorganism is E. coli. In some embodiments, the microorganism is derived from E. coli MG1655.

[0010] In some embodiments, the genetically modified microorganism comprises a nucleic acid sequence encoding a recombinant protein. In some embodiments, the nucleic acid sequence encoding the recombinant protein is located in the genome of the microorganism. In some embodiments, the nucleic acid sequence encoding the recombinant protein is located on a plasmid. In some embodiments, the recombinant protein is an RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase.

[0011] In some embodiments, the RNA polymerase comprises an amino acid modification relative to a wild-type RNA polymerase that results in (a) an amino acid substitution at a binding site residue for de novo RNA synthesis, and (b) an increased transcription efficiency. In some embodiments, the amino acid modification is an amino acid substitution at position 47 relative to a wild-type RNA polymerase, where the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the amino acid substitution at position 47 is G47A. In some embodiments, the amino acid modification comprises an additional C-terminal amino acid relative to a wild-type RNA polymerase. In some embodiments, the additional C-terminal amino acid is glycine. In some embodiments, the RNA polymerase comprises the amino acid sequence of SEQ ID NO: 41. In some embodiments, the RNA polymerase variant comprises an amino acid substitution at position 350 and / or an amino acid substitution at position 351 relative to a wild-type RNA polymerase, where the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the amino acid substitution at position 350 is E350W. In some embodiments, the amino acid substitution at position 351 is D351V. In some embodiments, the amino acid substitution at position 350 is E350W and the amino acid substitution at position 351 is D351V. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 43.

[0012] In some embodiments, the present disclosure relates to a method for producing a polypeptide or protein, comprising the steps of i) introducing a nucleic acid molecule comprising a sequence encoding the polypeptide or protein into one of the genetically modified microorganisms described herein, ii) culturing the genetically modified organism under conditions suitable for expression of the polypeptide or protein, and iii) isolating the polypeptide or protein.

[0013] In some embodiments, the present disclosure relates to a method for producing a polypeptide or protein, comprising the steps of i) culturing one of the genetically modified microorganisms described herein under conditions suitable for expression of the polypeptide or protein, and ii) isolating the polypeptide or protein.

[0014] In some embodiments of the methods described herein, the polypeptide or protein is an RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase. In some embodiments, the RNA polymerase comprises an amino acid modification relative to a wild-type RNA polymerase that results in (a) an amino acid substitution at a binding site residue for de novo RNA synthesis, and (b) an increased transcription efficiency. In some embodiments, the amino acid modification is an amino acid substitution at position 47 relative to a wild-type RNA polymerase, where the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the amino acid substitution at position 47 is G47A. In some embodiments, the amino acid modification comprises an additional C-terminal amino acid relative to a wild-type RNA polymerase. In some embodiments, the additional C-terminal amino acid is glycine. In some embodiments, the RNA polymerase comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the RNA polymerase variant comprises an amino acid substitution at position 350 and / or an amino acid substitution at position 351 relative to a wild-type RNA polymerase, where the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the amino acid substitution at position 350 is E350W. In some embodiments, the amino acid substitution at position 351 is D351V. In some embodiments, the amino acid substitution at position 350 is E350W and the amino acid substitution at position 351 is D351V. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 43.

[0015] The accompanying drawings are not drawn to scale. In the drawings, each identical or nearly identical component shown in various figures is represented by a similar numeral. For purposes of clarity, not every component is shown in every figure. The following drawings: [Brief description of the drawings]

[0016] [Figure 1] 1 shows the positive and negative selection strategies used to introduce gene knockouts into E. coli. [Diagram 2] 1 shows the lineage of E. coli strain construction carried out in the Examples. [Diagram 3] PCR confirmation of the genotype of strain 17 is shown. Seven different PCR reactions were performed using strain 17 colonies as template DNA, and the PCR amplicons were confirmed to be of the expected length, as shown in Table 5. 1 kb and a DNA ladder are shown in the left lane of lane 1. [Figure 4] Figure 1 shows expression of T7 RNA polymerase variant 1 using commercially available strains BL21 and strain 11. A shows a total protein gel of lysates of strain 11 and BL21 overexpressing T7 RNA polymerase variant 1. B shows growth profiles depicting final cell densities for both strain 11 and BL21. [Diagram 5] Strain 12 exhibits a mucoid phenotype, while strains 24 and 18 lack the mucoid phenotype. A shows the appearance of strains 12, 24 (BL21 host), and 18 in culture after shake flask fermentation. B shows the appearance of the strains after centrifugation of 100 uL of culture in a microcentrifuge tube. [Figure 6] 1 shows a total protein SDS-PAGE gel image of T7 RNA polymerase variant 1 overexpressed by strain 17. [Figure 7A] 1 shows the online AMBR profile and CER profile of the fermentation experiment. [Figure 7B] 1 shows the online AMBR profile of the fermentation experiment, showing the % dissolved oxygen. [Figure 7C] 1 shows the online AMBR profile of the fermentation experiment. [Figure 7D] 1 shows an online AMBR profile of a fermentation experiment, showing base addition. [Figure 7E] 1 shows the online AMBR profile of the fermentation run, with the injected acid shown. [Figure 7F] Figure 1 shows the online AMBR profile of the fermentation experiment. The feed profile is shown. Induction was performed at 9 hours and feeding was started at 13 hours. [Figure 8A] 1 shows expression of T7 RNA polymerase variant 2 by strain 19 (strain 17 transformed with pStrain 23). FIG. 1 shows SDS-PAGE of T7 RNA polymerase variant 2 expressed and purified from strain 19 (strain 17 / pStrain 23). [Figure 8B] Figure 1 shows expression of T7 RNA polymerase variant 2 by strain 19 (strain 17 transformed with pStrain 23). Specific T7 RNA polymerase variant 2 yields (mg protein per gram biomass) from strain 19 cell paste and concentrations of T7 RNA polymerase variant 2 in the lysate are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Genetically modified microorganisms Some aspects of the present disclosure relate to genetically modified microorganisms, including genomes in which the ompT and lon genes are mutated, disabled, or deleted. The genome of a microorganism, as used herein, refers to one or more chromosomes of a microorganism, and is a long DNA molecule required for cell survival and replication.

[0018] The ompT gene encodes the protein OmpT, an aspartyl protease commonly found in the outer membrane of Escherichia coli. When E. coli cells are lysed, OmpT in the outer membrane cleaves proteins such as T7 RNA polymerase that are otherwise stable in the cytoplasm, thereby reducing the amount of intact protein that can be isolated from E. coli cells expressing the protein (see, e.g., Grodberg et al. J Bacteriol. 1988.170(3):1245-1253). Thus, deleting the ompT gene from the genome increases the amount of protein that can be purified from the cells of the microorganism. An example of the DNA sequence of the ompT gene is given in accession number M23630.1 and is reproduced as SEQ ID NO:27. An example of the amino acid sequence of the OmpT protein is given in accession number P09169 and is reproduced as SEQ ID NO:28.

[0019] The lon gene encodes the protein Lon, an ATP-dependent serine protease involved in the degradation of denatured proteins, including mutant and abnormal proteins. Thus, the presence of Lon in the cells of a microorganism reduces the amount of protein that can be isolated from cells expressing the protein. An example of the DNA sequence of the lon gene is given under accession number M38347.1 and is reproduced as SEQ ID NO: 29. An example of the amino acid sequence of the Lon protein is given under accession number P0A9M0 and is reproduced as SEQ ID NO: 30. A gene or nucleic acid sequence is said to be mutated if it contains one or more modifications, such as an insertion, deletion, or substitution, relative to the wild-type sequence. An insertion is a modification in which the modified nucleic acid sequence differs from the wild-type nucleic acid sequence in that one or more nucleotides have been added relative to the wild-type sequence. A deletion is a modification in which the modified nucleic acid sequence differs from the wild-type sequence in that one or more nucleotides have been removed. A substitution is a modification in which the modified nucleic acid sequence differs from the wild-type sequence in that one nucleotide at a position in the sequence has been changed to a different nucleotide. A gene or nucleic acid sequence is said to be disabled if the protein encoded by the gene or nucleic acid sequence is reduced in function relative to the protein encoded by the wild-type gene or nucleic acid sequence. A gene or nucleic acid sequence is said to be deleted from a genome if the genome containing the gene or nucleic acid sequence is modified to not contain the gene or nucleic acid sequence after it has been modified. Mutation or deletion of a promoter operably linked to a gene or nucleic acid sequence often reduces expression of the gene, but if the gene or nucleic acid sequence is present in the genome, non-specific transcription by alternative promoters or RNA polymerases can result in transcription of the gene or nucleic acid sequence, resulting in the production of the encoded protein. Deleting a gene or nucleic acid sequence from a genome inhibits such transcription mechanisms and inhibits the production of the protein by cells harboring a genome in which the gene or nucleic acid sequence has been deleted.

[0020] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional ManA. ManA or mannose-6-phosphate isomerase is an enzyme encoded by the manA gene that catalyzes the conversion of D-fructose-6-phosphate to D-mannopyranose 6-phosphate or D-mannose-6-phosphate. This reaction is the first step of the pathway required for the synthesis of GDP-mannose. An example of this synthesis pathway in E. coli is described in Lee et al., Microb Cell Fact. 2012.11:48 (see, e.g., FIG. 1). Thus, suppressing ManA function inhibits mannose synthesis and, as a result, inhibits the synthesis of capsular polysaccharides containing mannose, which contributes to the mucoid phenotype of the bacterium. An example of the DNA sequence of the manA gene is given in accession number M15380.1 and is reproduced as SEQ ID NO: 31. An example of the amino acid sequence of the ManA protein is given in accession number P00946 and is reproduced as SEQ ID NO: 32. The absence of functional ManA in a cell renders the cell unable to produce GDP-mannose. Functional ManA refers to a form of ManA that can catalyze the conversion of D-fructose-6-phosphate to D-mannopyranose 6-phosphate or D-mannose-6-phosphate. A cell is said to lack or not express functional ManA if it expresses a form of ManA that does not catalyze the conversion of D-fructose-6-phosphate to D-mannopyranose 6-phosphate or D-mannose-6-phosphate, or if it does not express any ManA protein.

[0021] In some embodiments, the genome includes a mutation in the manA gene or in a promoter operably linked to the manA gene. Mutation, as used herein, refers to a modification of a nucleic acid sequence in which one or more nucleotides are replaced with a different nucleotide (substitution) or one or more nucleotides are added (inserted) or removed (deleted) from the sequence. A mutation in a nucleic acid sequence encoding a protein may change the amino acid sequence of the encoded protein. For example, a mutation that introduces a stop codon into the coding sequence (nonsense mutation) will result in a truncated form of the protein being translated. A mutation that introduces or removes a number of nucleotides other than a multiple of three (e.g., 1, 2, 4, or 5 nucleotides) will result in a different amino acid being encoded by the nucleic acid sequence starting at the position of the insertion or deletion (frameshift mutation). A mutation that changes a codon that codes for a first amino acid to a codon that codes for a different amino acid will result in a protein being translated with a different amino acid at the position corresponding to the codon where the substitution occurred (missense mutation). A mutation in a promoter may prevent RNA polymerase from interacting with the promoter to initiate transcription, thereby inhibiting expression of the nucleic acid sequence operably linked to the promoter. A promoter is a nucleic acid sequence that controls the expression of an operably linked gene or nucleic acid sequence. A promoter is said to be operably linked to a gene if the promoter controls the degree of expression of the gene. A promoter can be a constitutive promoter that causes the expression of an operably linked gene at a certain level. A promoter can be a conditional promoter that regulates the expression of an operably linked gene based on an environmental condition, such as the presence or amount of a stimulus, such as a small molecule, a protein, or a nucleic acid. In some embodiments, the genome does not include a nucleic acid sequence that codes for ManA.

[0022] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional G6PI. G6PI or glucose-6-phosphate isomerase is an enzyme encoded by the pgi gene that catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate, which is required for GDP-mannose synthesis. Thus, suppressing G6PI function inhibits mannose synthesis and, as a result, inhibits the synthesis of capsular polysaccharides containing mannose, which contributes to the mucoid phenotype of bacteria. An example of the DNA sequence of the pgi gene is given under accession number X15196 and is reproduced as SEQ ID NO: 49. An example of the amino acid sequence of the G6PI protein is given under accession number P0A6T1 and is reproduced as SEQ ID NO: 50. The lack of functional G6PI in a cell renders the cell unable to isomerize glucose-6-phosphate to fructose-6-phosphate. Functional G6PI refers to a form of G6PI that is capable of catalyzing the isomerization of glucose-6-phosphate to fructose-6-phosphate. A cell lacks expression of functional G6PI or does not express functional G6PI if it expresses a form of G6PI that does not catalyze the isomerization of glucose-6-phosphate to fructose-6-phosphate or does not express any G6PI protein. In some embodiments, the genome comprises a mutation in the pgi gene or in the promoter operably linked to the pgi gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding G6PI.

[0023] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional ManB. ManB or phosphomannomutase is an enzyme encoded by the manB gene, which catalyzes the conversion of D-mannose 6-phosphate to alpha-D-mannose 1-phosphate, which is required for GDP-mannose synthesis. Thus, suppressing ManB function inhibits mannose synthesis, and thus inhibits the synthesis of capsular polysaccharides containing mannose, which contributes to the mucoid phenotype of bacteria. ManB is also known in the art as CpsG and is encoded by the cpsG gene. An example of the DNA sequence of the manB gene is given in accession number AAC77847 and is reproduced as SEQ ID NO: 51. An example of the amino acid sequence of the ManB protein is given in accession number P24175 and is reproduced as SEQ ID NO: 52. The lack of functional ManB in a cell renders the cell unable to produce alpha-D-mannose 1-phosphate. Functional ManB refers to a form of ManB that can catalyze the conversion of D-mannose-6-phosphate to alpha-D-mannose 1-phosphate. A cell lacks expression of functional ManB or does not express functional ManB if it expresses a form of ManB that does not catalyze the conversion of D-mannose-6-phosphate to alpha-D-mannose 1-phosphate or does not express any ManB protein. In some embodiments, the genome comprises a mutation in the manB gene or in a promoter operably linked to the manB gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding ManB.

[0024] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional ManC. ManC or mannose-1-phosphate guanylyltransferase is an enzyme encoded by the manC gene, which catalyzes the conversion of alpha-D-mannose 1-phosphate to GDP-alpha-D-mannose, which is required for GDP-mannose synthesis. Thus, suppressing ManC function inhibits mannose synthesis, and thus inhibits the synthesis of capsular polysaccharides containing mannose, which contributes to the mucoid phenotype of bacteria. ManC is also known in the art as CpsB and is encoded by the cpsB gene. An example of the DNA sequence of the manC gene is given in accession number AAC77846 and is reproduced as SEQ ID NO: 53. An example of the amino acid sequence of the ManC protein is given in accession number P24174 and is reproduced as SEQ ID NO: 54. The lack of functional ManC in a cell renders the cell unable to produce GDP-alpha-D-mannose. Functional ManC refers to a form of ManC that can catalyze the conversion of alpha-D-mannose 1-phosphate to GDP-alpha-D-mannose. A cell lacks or does not express functional ManC if it expresses a form of ManC that does not catalyze the conversion of alpha-D-mannose 1-phosphate to GDP-alpha-D-mannose or does not express any ManC protein. In some embodiments, the genome comprises a mutation in the manC gene or in the promoter operably linked to the manC gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding ManC.

[0025] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional Gmd. Gmd or GDP-mannose 4,6-dehydratase is an enzyme encoded by the gmd gene that catalyzes the conversion of GDP-alpha-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose, which is required for GDP-L-fucose synthesis. Thus, suppressing Gmd function inhibits fucose synthesis and, as a result, inhibits the synthesis of capsular polysaccharides containing fucose, which contributes to the mucoid phenotype of bacteria. An example of the DNA sequence of the gmd gene is given in accession number AAC77842 and is reproduced as SEQ ID NO: 55. An example of the amino acid sequence of the Gmd protein is given in accession number P0AC88 and is reproduced as SEQ ID NO: 56. The lack of functional Gmd in a cell renders the cell unable to produce GDP-4-dehydro-6-deoxy-D-mannose. Functional Gmd refers to a form of Gmd that can catalyze the conversion of GDP-alpha-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose. A cell lacks expression of functional Gmd or does not express functional Gmd if it expresses a form of Gmd that does not catalyze the conversion of GDP-alpha-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose or does not express any Gmd protein. In some embodiments, the genome comprises a mutation in the gmd gene or in a promoter operably linked to the gmd gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding Gmd.

[0026] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express functional Fcl. Fcl or GDP-L-fucose synthase is an enzyme encoded by the fcl gene, which catalyzes the conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose, which is required for GDP-L-fucose synthesis. Thus, suppressing Fcl function inhibits fucose synthesis, and thus inhibits the synthesis of capsular polysaccharides containing fucose, which contribute to the mucoid phenotype of bacteria. Fcl is also known in the art as WcaG and is encoded by the wcaG gene. An example of the DNA sequence of the fcl gene is given in accession number AAC77843 and is reproduced as SEQ ID NO: 57. An example of the amino acid sequence of the Fcl protein is given in accession number P32055 and is reproduced as SEQ ID NO: 58. The lack of functional Fcl in a cell renders the cell unable to produce GDP-fucose. Functional Fcl refers to a form of Fcl that can catalyze the conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose. A cell lacks expression of functional Fcl or does not express functional Fcl if it expresses a form of Fcl that does not catalyze the conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose or does not express any Fcl protein. In some embodiments, the genome comprises a mutation in the fcl gene or in a promoter operably linked to the fcl gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding Fcl.

[0027] In some embodiments of the genetically modified microorganisms described herein, the microorganism does not express a functional KduI. KduI or 4-deoxy-L-threo-5-hexosulose-uronic acid ketol-isomerase is an enzyme encoded by the kduI gene that catalyzes the isomerization of 5-dehydro-4-deoxy-D-glucuronic acid to 3-deoxy-D-glycero-2,5-hexodiulosonic acid, the first step in hexuronic acid metabolism involved in the synthesis of extracellular polysaccharides that contribute to the mucoid phenotype of bacteria. An example of the DNA sequence of the kduI gene is given in accession number AAC75882 and is reproduced as SEQ ID NO: 59. An example of the amino acid sequence of the KduI protein is given in accession number Q46938 and is reproduced as SEQ ID NO: 60. The lack of a functional KduI in a cell renders the cell unable to produce 3-deoxy-D-glycero-2,5-hexodiulosonic acid. Functional KduI refers to a form of KduI that can catalyze the isomerization of 5-dehydro-4-deoxy-D-glucuronic acid to 3-deoxy-D-glycero-2,5-hexodiulosonic acid. A cell lacks expression of functional KduI or does not express functional KduI if it expresses a form of KduI that does not catalyze the isomerization of 5-dehydro-4-deoxy-D-glucuronic acid to 3-deoxy-D-glycero-2,5-hexodiulosonic acid or does not express any KduI protein. In some embodiments, the genome comprises a mutation in the kduI gene or in a promoter operably linked to the kduI gene. In some embodiments, the genome does not comprise a nucleic acid sequence encoding KduI.

[0028] In some embodiments, the genome comprises a first nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or up to 100% sequence identity to SEQ ID NO:23, and a second nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or up to 100% sequence identity to SEQ ID NO:25. In some embodiments, the genome includes a third nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or up to 100% sequence identity to SEQ ID NO:24.

[0029] In some embodiments of the genetically modified microorganisms described herein, the microorganisms do not exhibit a mucoid phenotype. Mucoid phenotype, as used herein, refers to a phenotype characterized by excessive production of sugars, such as polysaccharides. Microbial cells of mucoid phenotype tend to adhere to each other more easily than cells that are not mucoid phenotype, and the liquid in which microorganisms of mucoid phenotype grow has a consistency similar to that of mucus (see, for example, Hamelin et al. J Bacteriol.1975.122(1):19-24). The viscosity of this liquid medium and the extracellular polysaccharides present on the microbial cells hinder the mixing of bacteria during fermentation, reduce the amount of dissolved oxygen, and prevent the pelleting of microorganisms by centrifugation. Thus, microorganisms that do not contain a mucoid phenotype are more easily separated from liquid medium than microorganisms of mucoid phenotype.

[0030] Escherichia coli In some embodiments of the genetically modified microorganisms described herein, the microorganism is Escherichia coli (E. coli). In some embodiments, the microorganism is derived from E. coli MG1655. E. coli has been used as a host for plasmid DNA production for many years. Several different strains have been constructed for many different purposes, including cloning, plasmid DNA production, and protein expression. Most commonly, E. coli K12 derivatives used as DH5α, JM108, DH10β, etc. are used for cloning and production of plasmid DNA because they have certain genomic mutations that are desirable for cloning purposes. These are primarily those that inactivate genes that code for nucleases, recombinases, and other enzymes that reduce the DNA stability, purity, and cloning efficiency of the strain.

[0031] Furthermore, E. coli, among other organisms, possesses regulatory pathways that limit or regulate the expression of other products (e.g., nucleotides) that may be desirable to have in large quantities, making it difficult for E. coli to produce the desired products efficiently while the genes controlling these pathways are active.

[0032] In some embodiments, the genome does not contain a nucleic acid sequence encoding endA, the genome does not contain a nucleic acid sequence encoding recA, and the EcoK1 restriction system is inactivated. The endA gene encodes the endonuclease-1 protein, which induces double-strand break activity when expressed. This activity allows E. coli carrying the gene to degrade plasmid DNA, which would otherwise impair its production. The recA gene encodes the RecA protein, which is an important protein for DNA repair and maintenance. However, RecA plays a central role in DNA homologous recombination due to its properties of promoting DNA repair, mediating homologous pairing, homologous recombination, DNA break repair, and the SOS response, whereas DNA damage induces cell cycle arrest and the initiation of DNA repair and mutagenesis. The properties of both EndA and RecA are not beneficial for producing consistent and identical DNA plasmids.

[0033] Naturally occurring E. coli possesses the EcoKI restriction system. EcoKI is a restriction-modification enzyme complex responsible for identifying and restricting unmethylated foreign DNA and for modifying naturally hemimethylated DNA by methylation for self-identification. Left untreated, the EcoKI system will recognize unmethylated DNA as foreign and, if the DNA possesses its own EcoKI recognition site, will degrade it. It is not necessary to inactivate the EcoKI system of E. coli in order to clone plasmid DNA, but deleting it can greatly increase the efficiency of cloning and transformation if the desired plasmid DNA possesses an EcoKI recognition site.

[0034] In some embodiments, the genotype of the microorganism is ΔendA ΔrecA Δ(mrr-hsdRMS-symE-mcrBC) ΔompT ΔmanA Δlon. mrr encodes the restriction endonuclease Mrr, which cleaves methylated DNA at a specific recognition site. The hsdRMS operon encodes HsdR, HsdM, and HsdS, the three protein components of the EcoK1 restriction system, which cleave unmethylated DNA at a specific recognition site. symE encodes the endoribonuclease SymE. mcrBC encodes the restriction endonuclease McrBC, which cleaves methylated DNA at a specific recognition site.

[0035] Vectors encoding recombinant proteins The genetically modified microorganisms described herein, in some embodiments, comprise a nucleic acid sequence encoding a recombinant protein. As used herein, "recombinant protein" refers to a protein encoded by a nucleic acid sequence that has been cloned into an expression vector, such as a plasmid, and expressed from the vector by transcription of mRNA from the vector and translation of the resulting mRNA.

[0036] In some embodiments, the nucleic acid sequence encoding the recombinant protein is located in the genome of the microorganism. A nucleic acid is said to be located in a genome when the genome of the organism contains the nucleic acid sequence. In some embodiments, the nucleic acid sequence encoding the recombinant protein is located in a plasmid. A plasmid refers to a circular DNA molecule that is separate from the chromosome of the microorganism.

[0037] In some embodiments, the recombinant protein encoded by the nucleic acid sequence is an RNA polymerase. An RNA polymerase is a protein that binds to a template polynucleotide and synthesizes an RNA polynucleotide or transcript that includes an RNA sequence complementary to a sequence in the template polynucleotide. In some embodiments, the RNA polymerase is a DNA-dependent RNA polymerase that synthesizes an RNA transcript from a DNA template polynucleotide. In some embodiments, the RNA polymerase is an RNA-dependent RNA polymerase that synthesizes an RNA transcript from an RNA template polynucleotide. RNA polymerases include, but are not limited to, phage RNA polymerases, such as T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, K11 RNA polymerase, and / or mutant polymerases, such as, but not limited to, polymerases that are capable of incorporating modified nucleic acids. As a non-limiting example, an RNA polymerase can be modified to exhibit an increased ability to incorporate 2'-modified nucleotide triphosphates compared to unmodified RNA polymerases.

[0038] In some embodiments, the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase. An example of a DNA sequence encoding T7 RNA polymerase is given under accession number M38308.1 and is reproduced as SEQ ID NO: 33. An example of an amino acid sequence of T7 RNA polymerase is given under accession number P00573 and is reproduced as SEQ ID NO: 34. An example of a DNA sequence encoding T3 RNA polymerase is given under accession number X02981.1 and is reproduced as SEQ ID NO: 35. An example of an amino acid sequence of T3 RNA polymerase is given under accession number P07659 and is reproduced as SEQ ID NO: 36. An example of a DNA sequence encoding SP6 RNA polymerase is given under accession number Y00105.1 and is reproduced as SEQ ID NO: 37. An example of an amino acid sequence of SP6 RNA polymerase is given under accession number P06221 and is reproduced as SEQ ID NO: 38. An example of a DNA sequence encoding K11 RNA polymerase is given under the accession number X53238.1 and is reproduced as SEQ ID NO: 39. An example of an amino acid sequence of K11 RNA polymerase is given under the accession number P18147 and is reproduced as SEQ ID NO: 40.

[0039] In some embodiments, the RNA polymerase is an RNA polymerase variant. The RNA polymerase variant comprises at least one amino acid substitution relative to wild-type (WT) RNA polymerase. For example, with respect to WT T7 RNA polymerase having the amino acid sequence of SEQ ID NO: 34, glycine at position 47 is considered as a "wild-type amino acid", and the substitution of glycine at position 47 with alanine is considered as an "amino acid substitution" with high helical propensity. In some embodiments, the RNA polymerase variant is a T7 RNA polymerase variant comprising at least one (one or more) amino acid substitution relative to WT RNA polymerase (e.g., WT T7 RNA polymerase having the amino acid sequence of SEQ ID NO: 34).

[0040] In some embodiments, the RNA polymerase variant comprises an RNA polymerase comprising one (at least one) amino acid modification that results in a conformational change in the loop structure of the RNA polymerase variant to a helical structure when the RNA polymerase variant transitions from an initiation complex to an elongation complex. In some embodiments, the RNA polymerase variant comprises an amino acid modification that results in (a) an amino acid substitution at a binding site residue for de novo RNA synthesis, and (b) an increased transcription efficiency, relative to a wild-type RNA polymerase. In some embodiments, the amino acid modification is an amino acid substitution at position 47, relative to a wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. The amino acid substitution, in some embodiments, is a high propensity amino acid substitution. Examples of high helical propensity amino acids include alanine, isoleucine, leucine, arginine, methionine, lysine, glutamine, and / or glutamic acid. In some embodiments, the amino acid substitution at position 47 is G47A. In some embodiments, the RNA polymerase variant comprises an RNA polymerase that comprises an additional C-terminal amino acid relative to the wild-type RNA polymerase. The additional C-terminal amino acid, in some embodiments, is selected from glycine, alanine, threonine, proline, glutamine, serine. In some embodiments, the additional C-terminal amino acid (e.g., at position 884 relative to a wild-type RNA polymerase comprising the amino acid sequence of SEQ ID NO: 34) is glycine. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 41. In some embodiments, the RNA polymerase variant comprises an amino acid substitution at position 350 and / or an amino acid substitution at position 351 relative to a wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the amino acid substitution at position 350 is E350W. In some embodiments, the amino acid substitution at position 351 is D351V.In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO: 43.

[0041] Methods for recombinant protein production Some aspects of the present disclosure relate to methods for producing a polypeptide or protein, comprising the steps of i) introducing a nucleic acid molecule comprising a sequence encoding the polypeptide or protein into one of the genetically modified microorganisms described herein, ii) culturing the genetically modified organism under conditions suitable for expression of the polypeptide or protein, and iii) isolating the polypeptide or protein.

[0042] Introducing a vector into a microorganism refers to contacting the microorganism with the vector or donor organism under conditions such that the vector is incorporated into the cells of the microorganism. A vector may also be introduced by transformation, a process in which a cell acquires extracellular DNA from the environment. Transformation may be achieved by electroporation or electropermeabilization, a process in which a composition containing extracellular DNA and microbial cells is subjected to an electric pulse to transiently create holes in the cell wall and membrane(s), allowing the introduction of DNA into the cytoplasm of the cells. Transformation may also be achieved by heat shocking a composition containing extracellular DNA and competent microbial cells, in which case the composition is rapidly heated and cooled, resulting in the introduction of the extracellular DNA into the cytoplasm of the competent cells. A cell is said to be competent if it is capable of acquiring extracellular DNA from the environment. Cells may be naturally competent, capable of acquiring extracellular DNA, or may be induced to become competent, such as by incubation with one or more compounds that facilitate the DNA acquisition process. For example, chemically competent cells are cells that have been treated with salt, dimethyl sulfoxide (DMSO), and / or polyethylene glycol (PEG). 2 and / or CaCl2 Salts such as DMSO neutralize the negative charges on the phospholipids of cell membranes and the phosphate backbone of DNA, allowing DNA to associate with the cell surface rather than being repelled by it. DMSO weakens the lipid bilayer of cell membranes, reducing its thickness and increasing its permeability. Thus, cells made chemically competent by treatment with salts, DMSO, and / or PEG are more likely to acquire extracellular DNA than unmodified cells.

[0043] Vectors can be introduced by conjugation, a process in which a donor organism introduces vectors into cells of a recipient organism, such as a microorganism. In conjugation, a donor organism cell containing pili or hair-like appendages contacts a recipient organism cell, and the pili form a tunnel connecting the interior of the cells. One strand of DNA from the vector is then transferred via the pilus to the recipient cell. After this transfer, both cells, each containing a single strand from the vector, synthesize a complementary strand, so that each cell has two strands from the vector.

[0044] A vector can be introduced by transduction, a process in which DNA is introduced into a cell by a virus or viral vector. When a virus, such as a bacteriophage, infects a microorganism, the viral DNA is introduced into the cytoplasm of the microbial cell. If the bacteriophage contains the DNA sequence of a vector or plasmid, the microorganism will contain the vector plasmid after infection and can maintain and replicate the plasmid during cell division (see, e.g., Ammann et al. J Bacteriol. 2008.190(8):3083-3087).

[0045] Culturing a microorganism refers to incubating the microorganism in an environment that allows the microorganism to grow and replicate. The environment that allows the microorganism to grow and replicate varies depending on the microorganism. The environment can be a liquid or solid medium that contains nutrients that the microorganism uses to grow and replicate. Non-limiting examples of media that can be used to culture a microorganism include lysogeny broth, Luria-Bertani (LB) broth or agar, tryptone soy (TS) broth or agar, and Todd-Hewitt broth or agar.

[0046] Suitable conditions for expression of a polypeptide or protein will vary depending on the microorganism, the vector and / or nucleic acid sequence encoding the polypeptide or protein, and the polypeptide or protein itself. As described in the previous paragraph, the environment in which the microorganism is cultured must support its growth and replication and can be any liquid or solid medium known in the art.

[0047] When the nucleic acid sequence encoding the polypeptide or protein is present on a vector such as a plasmid, the vector must be maintained within the cell of the microorganism in order to express the polypeptide or protein. Methods for maintaining a vector in a microorganism are well known in the art. One method for maintaining a vector in a microorganism includes culturing the microorganism in the presence of an antibiotic that kills or inhibits the growth of cells that do not contain the vector, but allows the growth and replication of cells that contain the vector, if the vector encodes a protein that confers resistance to the action of the antibiotic to the cell.

[0048] When a nucleic acid sequence is operably linked to a conditional promoter, expression of the polypeptide or protein requires culturing the microorganism under conditions in which the conditional promoter is active. For example, the lac operon in many bacteria is active only in the presence of lactose in the cell. The lac repressor protein complex binds to the lac operator, a nucleic acid sequence located between the lac promoter and the genes encoded by the lac operon, and inhibits transcription of the genes encoded by the lac operon. Allolactose, an isomer of lactose, binds to the lac repressor and induces a conformational change that dissociates the lac repressor from the operator, thereby allowing transcription of the encoded genes. If a lac operator is present upstream of the nucleic acid sequence encoding the gene or polypeptide to be expressed, the polypeptide or protein will only be expressed in the presence of allolactose or a similar compound such as isopropyl-β-D-thiogalactopyranoside (IPTG), and expression can be controlled by adjusting the amount of IPTG in the culture environment (see, e.g., Donovan et al. J Ind Microbiol. 1996.16(3):145-54).

[0049] Methods for isolating polypeptides or proteins are well known in the art (see, for example, Wingfield. Curr Protoc Protein Sci. 2016.80:6.1.1-6.1.35). Generally, bacteria expressing the protein are pelleted by centrifugation to separate the bacterial cells from the liquid medium. The bacterial cells are then lysed, such as by mechanical treatment with a French press or enzymatic treatment with lysozyme. The bacterial lysate is centrifuged to pellet the cellular components. If the recombinant protein is present in the cytoplasm or periplasm of the bacterial cells, the protein is purified from the lysate supernatant. If the recombinant protein is present in inclusion bodies, the lysate pellet is treated with Triton, EDTA, and / or urea to extract cell membrane components and solubilize the remaining inclusion bodies. The denatured protein can then be purified from the solubilized inclusion bodies and, if necessary, refolded into a desired conformation.

[0050] Some aspects of the present disclosure relate to methods for producing a polypeptide or protein, comprising: i) culturing one of the genetically modified microorganisms described herein under conditions suitable for expression of the polypeptide or protein; and ii) isolating the polypeptide or protein.

[0051] In some embodiments of the methods described herein, the polypeptide or protein is an RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase. In some embodiments, the RNA polymerase is an RNA polymerase variant. The RNA polymerase variant comprises at least one amino acid substitution relative to wild-type (WT) RNA polymerase. For example, with respect to WT T7 RNA polymerase having the amino acid sequence of SEQ ID NO: 34, glycine at position 47 is considered as a "wild-type amino acid", and the substitution of glycine at position 47 with alanine is considered as an "amino acid substitution" with high helical propensity. In some embodiments, the RNA polymerase variant is a T7 RNA polymerase variant comprising at least one (one or more) amino acid substitution relative to WT RNA polymerase (e.g., WT T7 RNA polymerase having the amino acid sequence of SEQ ID NO: 34).

[0052] In some embodiments, the RNA polymerase variant comprises an RNA polymerase comprising one (at least one) amino acid modification that results in a conformational change in the loop structure of the RNA polymerase variant to a helical structure when the RNA polymerase variant transitions from an initiation complex to an elongation complex. In some embodiments, the RNA polymerase variant comprises an amino acid modification that results in (a) an amino acid substitution at a binding site residue for de novo RNA synthesis, and (b) an increased transcription efficiency, relative to a wild-type RNA polymerase. In some embodiments, the amino acid modification is an amino acid substitution at position 47, relative to a wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO: 34. The amino acid substitution, in some embodiments, is a high propensity amino acid substitution. Examples of high helical propensity amino acids include alanine, isoleucine, leucine, arginine, methionine, lysine, glutamine, and / or glutamic acid. In some embodiments, the amino acid substitution at position 47 is G47A.

[0053] In some embodiments, the RNA polymerase variant comprises an RNA polymerase that comprises an additional C-terminal amino acid relative to the wild-type RNA polymerase. The additional C-terminal amino acid, in some embodiments, is selected from glycine, alanine, threonine, proline, glutamine, serine. In some embodiments, the additional C-terminal amino acid (e.g., at position 884 relative to a wild-type RNA polymerase comprising the amino acid sequence of SEQ ID NO:34) is glycine. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO:41. In some embodiments, the RNA polymerase variant comprises an amino acid substitution at position 350 and / or an amino acid substitution at position 351 relative to a wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO:34. In some embodiments, the amino acid substitution at position 350 is E350W. In some embodiments, the amino acid substitution at position 351 is D351V. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO:42. In some embodiments, the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO:43.

[0054] nucleic acid A "nucleic acid" is at least two nucleotides covalently linked together, which in some cases may contain a phosphodiester bond (e.g., a phosphodiester "backbone"). As used herein, the terms "nucleic acid sequence" and "polynucleotide" are used interchangeably and no length limitations are intended. As used herein, the terms "nucleic acid" and "nucleotide" are used interchangeably. The terms "nucleic acid sequence" and "polynucleotide" encompass DNA (including cDNA) and RNA sequences. The nucleic acid sequences described herein include nucleic acid sequences removed from their naturally occurring environment, recombinant or clonal DNA isolates, and chemically synthesized analogs or biologically synthesized analogs by heterologous systems.

[0055] An "engineered nucleic acid" is a nucleic acid that does not occur in nature. However, it should be understood that an engineered nucleic acid may contain naturally occurring nucleotide sequences that are not naturally occurring as a whole. In some embodiments, an engineered nucleic acid contains nucleotide sequences from different organisms (e.g., different species). For example, in some embodiments, an engineered nucleic acid contains bacterial nucleotide sequences, human nucleotide sequences, and / or viral nucleotide sequences. Engineered nucleic acids include recombinant and synthetic nucleic acids. A "recombinant nucleic acid" is a molecule constructed by combining nucleic acids (e.g., isolated nucleic acids, synthetic nucleic acids, or combinations thereof) that, in some embodiments, can replicate in a living cell. A "synthetic nucleic acid" is a molecule that has been amplified or that has been synthesized chemically or otherwise. Synthetic nucleic acids include those that have been chemically modified or otherwise modified, but are capable of base pairing with naturally occurring nucleic acid molecules. Recombinant and synthetic nucleic acids also include molecules that result from replication of any of the foregoing. A nucleic acid may contain naturally occurring nucleotides and / or non-naturally occurring nucleotides, such as modified nucleotides.

[0056] Engineered nucleic acids can be produced using standard molecular biology methods. In some embodiments, engineered nucleic acids are produced using GIBSON ASSEMBLY® cloning (see, e.g., Gibson, DG et al. Nature Methods, 343-345, 2009; and Gibson, DG et al. Nature Methods, 901-903, 2010). GIBSON ASSEMBLY® typically uses three enzyme activities in a one-tube reaction: 5' exonuclease, 3' extension activity of DNA polymerase, and DNA ligase activity. The 5' exonuclease activity chews back the 5' end sequence, exposing complementary sequences for annealing. The polymerase activity then fills in the gaps in the annealing region. The DNA ligase then seals the nicks and covalently joins the DNA fragments. The overlapping sequences of adjacent fragments are much longer than those used in Golden Gate Assembly, resulting in a higher rate of correct assembly.

[0057] The nucleic acid vectors described herein may also have one or more terminator sequences present or removed.Terminator sequences are nucleic acid sequences that signal the end of an expression cassette or transcription region.For efficient transcription, vectors typically contain one or more terminator sequences.Terminator sequences include, for example, T7 and T4 terminator sequences.

[0058] The preferred vectors described herein may carry a resistance marker, or a marker that is unique to the particular vector. For example, the vector may originally have an ampicillin resistance marker. In some embodiments described herein, the ampicillin marker is replaced with a different marker, such as a kanamycin resistance marker. In some embodiments, the E. coli genome disclosed herein may further express a gene for a positive selection marker based on a first environmental factor or a negative selection marker based on a second environmental factor, where the first and second environmental factors are not the same. In some embodiments, the E. coli genome disclosed herein may further express a gene for a positive selection marker based on a first environmental factor and a negative selection marker based on a second environmental factor, where the first and second environmental factors are not the same. In some embodiments, the positive selection marker is a gene capable of conferring kanamycin resistance. In some embodiments, the negative selection marker is a gene capable of expressing levansucrase.

[0059] The vectors disclosed herein may also be removed of any pathogen-derived sequences, which can have a positive effect on production yields.

[0060] The nucleic acid described herein includes an origin of replication (ori) and can be modified as disclosed herein. In some embodiments, the nucleic acid can contain several ori, for example, two ori. For example, it can be a combination of a low copy number ori and a temperature-dependent ori, or it can be an ori that allows amplification in various host organisms, for example.

[0061] Nucleic acid may also contain one or more elements from other known vectors.For example, other vectors include phage, cosmid, phasmid, fosmid, bacterial artificial chromosome, yeast artificial chromosome, virus and retrovirus (e.g., vaccinia, adenovirus, adeno-associated virus, lentivirus, herpes simplex virus, Epstein-Barr virus, fowlpox virus, pseudorabies, baculovirus) and vectors derived therefrom.In other embodiments, the nucleic acid described herein does not contain any elements from one or more other vectors.

[0062] The term "isolated," in the context as used herein, when applied to a nucleic acid sequence, indicates that the polynucleotide sequence has been removed from its natural genetic environment and is therefore free of other foreign or unwanted coding sequences (but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators) and is in a form suitable for use within engineered protein production systems. Such isolated molecules are ones that are separated from their natural environment.

[0063] There are many established algorithms available for aligning two nucleic acid sequences. Typically, one sequence can serve as a reference sequence, with which test sequences can be compared. Sequence comparison algorithms calculate the percentage of sequence identity of test sequence(s) to reference sequence based on designated program parameters. Alignment of nucleic acid sequences for comparison can be performed, for example, by computer-implemented algorithms (e.g., GAP, BESTFIT, FASTA or TFASTA), or BLAST and BLAST2.0 algorithms.

[0064] In sequence identity comparisons, identity can exist over a region of a sequence that is 10 nucleic acid residues in length (e.g., at least 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, or 685 nucleotides in length, e.g., up to the full length of the reference sequence.

[0065] Substantially homologous or substantially identical nucleic acids have one or more nucleotide substitutions, deletions, or additions. In many embodiments, these changes are minor in nature, and include only conservative nucleic acid substitutions, which may result in the same amino acid encoded during translation, or different but conservative amino acid substitutions. Conservative amino acid substitutions are made by replacing one amino acid with another amino acid in the following group: basic: arginine, lysine, histidine; acidic: glutamic acid, aspartic acid; polar: glutamine, asparagine; hydrophobic: leucine, isoleucine, valine; aromatic: phenylalanine, tryptophan, tyrosine; small: glycine, alanine, serine, threonine, methionine. Substantially homologous nucleic acids also include those that include other substitutions that do not significantly affect the folding or activity of the translation product.

[0066] The nucleic acid vectors described herein may be empty vectors or may contain an insert that may be an expression cassette or an open reading frame (ORF). An "open reading frame" is a continuous stretch of DNA that begins with a start codon (e.g., methionine (ATG)) and ends with a stop codon (e.g., TAA, TAG, or TGA) and encodes a protein or peptide. An expression cassette encodes an RNA that includes at least the following elements: a 5' untranslated region, a region encoding the open reading frame mRNA, a 3' untranslated region, and a polyA tail. An open reading frame can encode any mRNA.

[0067] "5' untranslated region (UTR)" refers to the region of an mRNA that is immediately upstream (i.e., 5') of the start codon (i.e., the first codon of an mRNA transcript that is translated by ribosomes) and does not code for a protein or peptide.

[0068] "3' untranslated region (UTR)" refers to the region of an mRNA that is immediately downstream (i.e., 3') of the stop codon (i.e., the codon of an mRNA transcript that signals the end of translation) and that does not encode a protein or peptide.

[0069] A "poly-A tail" is a region of an mRNA that is downstream, e.g., immediately downstream (i.e., 3'), of the 3'UTR and contains multiple consecutive adenosine monophosphates. A poly-A tail can contain 10 to 300 adenosine monophosphates. For example, a poly-A tail can contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 adenosine monophosphates. In some embodiments, a poly-A tail contains 50 to 250 adenosine monophosphates. In relevant biological environments (e.g., within a cell, in vivo, etc.), the poly(A) tail functions to protect the mRNA from enzymatic degradation, for example in the cytoplasm, and assists in transcription termination, transport of the mRNA from the nucleus, and translation.

[0070] Those skilled in the art recognize that different species exhibit "preferential codon usage". As used herein, the term "preferential codon usage" refers to the codons most frequently used in cells of a particular species, and thus one or a few representatives of the possible codons encoding each amino acid are preferred. For example, the amino acid threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian host cells, ACC is the most commonly used codon, and in other species, a different Thr codon may be preferred. The preferred codons for a particular host cell species can be introduced into the polynucleotides described herein by various methods known in the art. Alternatively, non-preferred codons may be used. In some embodiments, the nucleic acid sequence is codon-optimized. Methods of codon optimization are known in the art.

[0071] A "fragment" of a polynucleotide of interest comprises a contiguous stretch of nucleotides from the sequence of the full-length polynucleotide. By way of example, a "fragment" of a polynucleotide of interest may comprise (or consist of) at least 30 contiguous nucleotides from the sequence of the polynucleotide (e.g., at least 35, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 contiguous nucleic acid residues of the polynucleotide).

[0072] A "nucleic acid vector" is a polynucleotide that carries at least one foreign or heterologous nucleic acid fragment. A nucleic acid vector can function as a "molecular carrier" to deliver a polynucleotide of each of the nucleic acid fragments to a host cell or as a template for IVT. "In vitro transcription template (IVT)" as used herein refers to a deoxyribonucleic acid (DNA) suitable for use in an IVT reaction for the production of messenger RNA (mRNA). In some embodiments, an IVT template encodes a 5' untranslated region, contains an open reading frame, encodes a 3' untranslated region and a polyA tail. The composition and length of the specific nucleotide sequence of the IVT template depends on the mRNA of interest encoded by the template.

[0073] In some embodiments, the nucleic acid vector described herein is a circular nucleic acid such as a plasmid. In other embodiments, it is a linear nucleic acid. According to one embodiment, the nucleic acid vector comprises a predetermined restriction site, which can be used to linearize the vector. The restriction site determines where the vector nucleic acid is opened / linearized, so it is important to place the linearization restriction site intelligently. The restriction enzyme selected for linearization should preferably not cut within the critical components of the vector.

[0074] The terms 5' and 3' are used herein to describe features of a nucleic acid sequence related to either the location of a genetic element and / or the direction of an event (5'→3') (e.g., transcription by RNA polymerase or translation by ribosomes proceeding in a 5' to 3' direction). Synonyms are upstream (5') and downstream (3'). Conventionally, DNA sequences, genetic maps, vector cards and RNA sequences are drawn from left to right from 5' to 3' or the 5' to 3' direction is indicated by an arrow, the arrow pointing in the 3' direction. Thus, following this convention, 5' (upstream) refers to a genetic element located on the left hand side and 3' (downstream) refers to a genetic element located on the right hand side. EXAMPLES

[0075] Example 1: Production of T7 RNA polymerase variant 1 and T7 RNA polymerase variant 2 in genetically modified E. coli strains defective in Lon, OmpT, and ManA preface The aim of the work described in this example was to generate an E. coli strain for recombinant protein expression. Both lon and ompT ORFs were completely deleted from strain 2, which accepts and maintains plasmid DNA and can be purified from the host since the EcoKI restriction system, endA and recA have been deleted from the genome. A robust strain for plasmid-mediated enzyme expression was successfully generated that has a greatly reduced protease activity and therefore produces recombinant enzyme in high purity.

[0076] method [Table 1] [Table 2] [Table 3-1] [Table 3-2] [Table 4-1] [Table 4-2]

[0077] Construction of knockout cassettes The knockout cassette for the work in engineering the strain contained a DNA cassette encoding a kanamycin resistance marker (kan) in addition to sacB (encoding the levansucrase enzyme) for negative selection. To allow for the integration of this kan-sacB knockout cassette at the correct location in the genome, small upstream and downstream homology regions (UHR and DHR, respectively) of 45 bp were added onto the knockout cassette using PCR (Figure 1) and Invitrogen Platinum SuperFi PCR Master Mix. The knockout cassette was amplified from the in-house plasmid pStrain22, which contains the kan-sacB expression cassette.

[0078] Introduction of scarless genome deletions in E. coli The strains to be genetically modified were first transformed with pStrain21 and transformants were selected by plating on LB animal-free (LBAF) agar containing 100 μg / ml carbenicillin. A single transformant was then grown in LBAF broth containing 100 μg / ml carbenicillin for 16 hours at 30° C., after which 30 μl of this overnight culture was transferred to a test tube containing 3 ml of LBAF broth with 100 μg / ml carbenicillin and incubated at 30° C. and 250 rpm for 2 hours. After 2 hours of incubation, expression of the genes encoding the lambda red system and the codon-optimized E. coli recA was induced using 100 ng / ml anhydrotetracycline and 1 mM isopropyl β-D-1-thiogalactopyranoside, respectively. After a further 2-3 hours of shaking incubation at 30°C, 1 ml of the culture was harvested when the OD600 was approximately 0.6-1.0 to prepare 0.1 ml of electrocompetent cells. 50 ul of electrocompetent cells were mixed with 1 μg of purified knockout cassette and electroporated at 1800 volts in a 1 mm gap cuvette. Transformants were rescued in 1 ml of SOC medium at 30°C, 300 rpm for 2 hours, then plated on LBAF agar containing 50 μg / ml kanamycin and 100 μg / ml carbenicillin and incubated overnight at 30°C. Primary integrants were then screened using Colony PCR (cPCR) with LongAmp Taq DNA polymerase, using a universal primer that binds to the kanamycin resistance gene kan and a site-specific primer that binds upstream of the gene to be knocked out. In parallel with the cPCR, the same clones were spotted onto LBAF agar containing 35 μg / ml kanamycin and 100 μg / ml carbenicillin and onto LB agar containing 60 g / l sucrose. These plates were incubated overnight at 30° C. After confirmation of the primary integrants by cPCR, the expected sucrose sensitivity was confirmed by visually checking the "no growth" phenotype of spotted clones on LBAF agar containing 60 g / l sucrose.Once the primary integrant clones were identified by cPCR and were also confirmed to be sucrose sensitive, the knockout cassette was removed using an approach similar to that described below.

[0079] To remove a given knockout cassette and obtain a scarless deletion, linear dsDNA fragments containing only the UHR and DHR regions were amplified from gBlock (IDT) and unique primer sets shown in Table 1. For convenience, these linear dsDNA fragments used to remove the kan-sacB cassette are called "pop-out cassettes". Confirmed primary integrants were grown in LBAF broth containing 100 μg / ml carbenicillin and 50 μg / ml kanamycin for 16 hours at 30°C, and then 30 ul of this overnight culture was transferred to a test tube containing 3 ml of LBAF broth containing 100 μg / ml carbenicillin and 50 μg / ml kanamycin and incubated at 30°C, 250 rpm for 2 hours. After 2 hours of incubation, expression of the genes encoding the lambda red system and the codon-optimized E. coli recA was induced using 100 ng / ml aTc and 1 mM IPTG, respectively. After a further 2-3 hours of shaking incubation at 30°C, 1 ml of the culture was harvested when the OD600 was approximately 0.6-1.0 to prepare 0.1 ml of electrocompetent cells. 50ul of electrocompetent cells were mixed with 1μg of purified pop-out cassette and electroporated at 1800 volts in a 1mm gap cuvette. Transformants were rescued in 1ml of SOC medium at 30°C, 300 rpm for 2 hours and then transferred to a 125ml shake flask containing 9ml of LBAF broth. This diluted culture was then grown at 30°C, 300 rpm for 5-16 hours, after which 50ul of culture was transferred (filter sterilized through a 0.2uM filter) to a test tube containing 5ml of LBAF salt-free broth containing sucrose (10g / l soytone, 5g / l yeast extract, 60g / l sucrose). This sucrose-containing culture was then incubated overnight (approximately 16 hours) at 30° C. and 250 rpm. The grown culture was then diluted 1:1 million in sterile LBAF broth and plated (200 μl plating) onto LBAF agar and incubated overnight at 37° C.

[0080] Once isolated colonies were obtained on LBAF agar plates, clones were screened for successful removal of the knockout cassette (kan-sacB) using cPCR and primers binding upstream and downstream of the gene(s) to be knocked out. In parallel, clones were spotted in duplicate on LBAF agar and on LBAF agar containing 100 μg / ml carbenicillin. These plates were incubated overnight (16 hours) at 30° C. to confirm the loss of the temperature-sensitive plasmid pStrain21 required for genome editing. The DNA sequences of the linear pop-out cassettes used to construct strains 11 and 17 are shown in the exemplary sequence listing.

[0081] Stock confirmation for stock 17 PCR was performed to confirm the genotype of strain 17. Template DNA was isolated using scrapings from a glycerol stock of strain 17. PCR reactions were set up using appropriate primers for each target gene (Table 3) and LongAmp Taq DNA polymerase (catalog no. M0323S). When the gel in Figure 3 was analyzed, all band patterns were consistent with the expected molecular weights for the edited loci. The sequences of the PCR products were also checked to verify that the expected mutations had been introduced at the desired loci. [Table 5]

[0082] result T7 RNA polymerase variant 1 expression by strain 11 Strain 11 / p strain 2 and BL21 / p strain 2 clones were incubated overnight at 30°C, 300 rpm. The next day, 500 mL baffled shake flasks were prepared containing 60 ml of TBAF++ and 50 μg / ml kanamycin. A portion of each overnight grown culture was transferred to a flask to obtain an initial OD600=0.05. The flasks were then incubated at 28°C, 300 rpm for the duration of the experiment. At 12 hours, the flasks were induced with 1 mM IPTG (approximate OD600=15). Every hour after induction, OD600 was measured and cell pellets corresponding to 1 OD600 were stored at -20°C for lysis and protein gel.

[0083] After successful generation of strain 11, it was transformed with plasmid pStrain2 to generate strain 12, which allows high copy IPTG inducible expression of T7 RNA polymerase variant 1. The growth profile, characteristics, T7 RNA polymerase variant 1 protein yield and purity of strain 12 were first assayed in shake flasks as described in the methods section. The shake flask study also included BL21 with pStrain2 as a comparison. As shown in Figure 4, the growth and expression of T7 RNA polymerase variant 1 enzyme of strain 12 is comparable to BL21. BL21 also showed degradation of T7 RNA polymerase variant 1 that was not observed in strain 11. Unfortunately, strain 11 showed a negative growth phenotype, resulting in a very viscous slurry-like culture. This resulted in poor mixing performance of the Ambr bioreactor, reduced oxygen mass transfer and reduced ability to maintain the desired dissolved oxygen % (data not shown).

[0084] The mucoid phenotype appears to be a result of the lon deletion, since the ompT knockout of strain 10 by itself shows normal growth and culture appearance (data not shown). Without wishing to be bound by theory, complete removal of Lon may cause excessive accumulation of RcsA, resulting in overproduction of a polysaccharide called colanic acid. Therefore, manA, the gene encoding the first step of the mannose biosynthetic pathway, was removed from the genome. Removal of this nonessential gene from the genome eliminated the overproduction of polysaccharides and abolished the mucoid phenotype.

[0085] manA knockout abolishes the undesirable mucoid phenotype Strain 17 was constructed to demonstrate that the manA knockout eliminates the mucoid phenotype resulting from the required lon knockout. Strains 11, BL21, and 17 were transformed with pStrain2 (for expression of T7 RNA polymerase variant 1) to obtain strains 12, 24, and 18, respectively. As can be clearly seen from FIG. 5A, strain 12 (strain 11 / pStrain2) shows dense mucoid formation as evidenced by the absence of foaming or trapped air bubbles. On the other hand, strains 24 and 18 (host strains BL21 and 17, respectively) show a normal phenotype in the presence of a plasmid encoding T7 RNA polymerase variant 1. To further demonstrate the improved cell morphology and its utility in industrial processes, cultures of strains 12, 24, and 18 were pelleted by centrifugation at 13,000×g. As shown in FIG. 5B, strain 24 (BL21 / pStrain2) formed a dense pellet. In contrast, strain 12, with intact manA (strain 11 / pStrain 2), did not pellet well. However, the manA knockout strain, strain 18 (strain 17 / pStrain 2), formed a crisp, dense pellet with a clear supernatant. These results from shake flask fermentations further supported the testing of strain 17 for recombinant protein expression in shake flasks and Ambr250 bioreactors.

[0086] Expression of T7 RNA polymerase variant 1 by host strain 17 To perform expression fermentations in shake flasks, strain 17 / p strain 2 clones were inoculated into 3 ml tubes of LBAF containing 50 μg / ml kanamycin and incubated overnight at 30° C. and 300 rpm. The OD600 of each culture was determined and the amount of each culture required to obtain an initial OD600=0.1 was transferred to a sterile baffled, vented 250 ml shake flask containing 30 ml TBAF + 50 μg / ml kanamycin. The inoculated flasks were then incubated at 37° C. and 300 rpm. At 3 hours, 0.5 mM IPTG was added to induce expression of T7 RNA polymerase variant 1. Four hours after inoculation, the OD600 and cell pellets corresponding to 1 OD were harvested.

[0087] In this study, four different clones expressing T7 RNA polymerase variant 1 in strain 17 were evaluated. In Figure 6, overexpression of T7 RNA polymerase variant 1 was observed in all clones, but clone 1 appeared to have the highest expression of T7 RNA polymerase variant 1. Possibly due to the lack of a mucoid phenotype, lysis was more efficient compared to the experiment using strain 11 as the host strain, resulting in a cleaner gel image.

[0088] Performance of T7 RNA polymerase variant 2 expressing strain 17 in Ambr250 bioreactors After transformation of strain 17 with pStrain23 carrying an IPTG-inducible DNA sequence encoding T7 RNA polymerase variant 2, two clones, strain 19 and strain 20, were selected for further screening and characterization. Once the plasmids and genotypes of the clones were confirmed, their performance in an AMBR250 bioreactor was evaluated. The process involves aerobic fed-batch fermentation using TBAF medium, yeastolate, and glycerol feed.

[0089] For this experiment, one 500 mL shake flask was inoculated with 75 mL of TBAF + 50 μg / mL kanamycin using ice scrapings from the glycerol stock and grown for 9.5 hours at 28° C. Each bioreactor was inoculated with 6.7% of the inoculum (initial OD 600 0.05). This was calculated based on an initial starting volume of 200 mL and then multiplied by the target OD600 of the seed flask of 0.8. This value was then normalized by the actual OD600 of the seed flask. [Table 6]

[0090] The online profiles were as expected and consistent between all bioreactors (Figure 7). The CER reached a value of 60 at 9 hours, prompting induction of all four bioreactors with IPTG bolus addition. The CER continued to rise throughout the culture period, reaching a peak CER of 90. Dissolved oxygen was maintained at 50% throughout the culture period with only minor fluctuations typical of these sensors. pH was maintained at the desired 6.95 ± 0.05. The pH rose above 7.0 during the exponential phase, prompting acid to be added until the pH stabilized around the 11th hour. Once the pH stopped rising and began to stabilize at the 11th hour, base was fed at a near constant rate to maintain the pH at 6.95. At 28 hours, the culture was harvested and sent for purification and LabChip analysis (protein quantification by capillary electrophoresis). Clonal strain 19 and strain 20 showed similar behavior, both growing to similar final wet cell weights (Table 6), and importantly, no issues were observed using the host strain, strain 17, for recombinant protein expression in high-density bioreactor fermentation.

[0091] Finally, expression of T7 RNA polymerase variant 2 was visualized, quantified, and purified from frozen cell pellets harvested during the Ambr fermentation described above. Cell pellets from strain 19 bioreactors were frozen at -80°C, thawed to ambient temperature, and treated by lysing the bacterial cells in the presence of Tris-HCl, NaCl, DTT, protease inhibitors, PMSF, lysozyme, DNAse, and Triton-X 100. The lysate was filtered, and the T7 RNA polymerase variant 2 present in the filtrate was analyzed by capillary electrophoresis. The results are shown in Figure 8. The final protein yield obtained was approximately 2.5 g / L (grams of protein per liter of culture) with a purity of >95% by densitometry. The yield of T7 RNA polymerase variant 2 achieved here is quite high for a first generation strain and fermentation process, and successful scale-up to a 30 L fermentation is expected to yield >60 grams of crude T7 enzyme per fermentation batch. In addition, approximately 1 g of T7 RNA polymerase is required to produce 100 to 150 g of mRNA.

[0092] conclusion A custom E. coli strain was developed to express recombinant proteins. First, strain 2 was selected as the parent strain to begin the introduction of genomic modifications that are particularly beneficial for recombinant protein expression. Strain 2 carries several mutations that are useful for industrial protein expression strains. These include endA and recA knockouts to increase plasmid stability and purity during purification, and inactivation of the EcoKI restriction system to improve transformation and cloning efficiency. The goal of this work was to reduce the protease activity of strain 2 to provide a strain capable of expressing recombinant enzymes with high purity.

[0093] The ompT gene, which encodes the major protease present in the outer membrane of E. coli, was removed from the genome. Secondly, the major housekeeping protease Lon was removed from the genome. It was discovered that the lon knockout of this strain resulted in a negative mucoid phenotype caused by upregulation of the polysaccharide synthesis pathway. This lon knockout was shown to reduce the performance of the Ambr250 bioreactor because the viscosity of the culture became a limitation for agitation and aeration of the culture. According to the genome sequence of Ecoli BL21 (Genbank: CP053601.1), the lon ORF remains intact in this strain. BL21 may not exhibit a mucoid phenotype because it exhibits some residual Lon activity. The strain was completely deficient in Lon activity to prevent degradation of the desired recombinant protein. To develop a strain that is a true lon knockout but does not exhibit a mucoid phenotype, an additional gene knockout, ΔmanA, was introduced to remove the first step of the non-essential polysaccharide synthesis pathway. The final genotype of strain 17, the first generation protein expression strain, is E. coli MG1655 ΔendA ΔrecA Δ(mrr-hsdRMS-symE-mcrBC) ΔompT ΔmanA Δlon.

[0094] Example 2: Production of T7 RNA polymerase variant 3 and T7 RNA polymerase variant 3 in genetically modified E. coli strains defective in Lon, OmpT, and ManA pStrain23, which encodes an IPTG-inducible DNA sequence encoding T7 RNA polymerase variant 2, is modified by site-directed mutagenesis such that its coding sequence instead encodes T7 RNA polymerase variant 3. This modified plasmid is designated pStrain24. Strain 17 is transformed with pStrain24 carrying an IPTG-inducible DNA sequence encoding T7 RNA polymerase variant 3. Once the genotype of the bacterial strain and transformed plasmid have been confirmed, the strain is inoculated into an AMBR250 bioreactor to initiate fermentation and production of T7 RNA polymerase variant 3. The process involves aerobic fed-batch fermentation using TBAF medium, yeastolate, and glycerol feed.

[0095] IPTG is added to each bioreactor to induce expression of T7 RNA polymerase variant 3. The bacterial cultures are grown and then harvested and sent for purification of T7 RNA polymerase variant 3 and subsequent LabChip analysis (protein quantification by capillary electrophoresis).

[0096] Finally, expression of T7 RNA polymerase variant 3 is visualized, quantified, and purified from frozen cell pellets harvested during the Ambr fermentation described above. Cell pellets from strain 19 bioreactors are frozen at -80°C, thawed to ambient temperature, and treated by lysing the bacterial cells in the presence of Tris-HCl, NaCl, DTT, protease inhibitors, PMSF, lysozyme, DNAse, and Triton-X 100. The lysate is filtered, and the T7 RNA polymerase variant 3 present in the filtrate is analyzed by capillary electrophoresis. When scaled up to a 30L fermentation, the fermentation is expected to yield more than 60 grams of unpurified T7 RNA polymerase variant 3 enzyme per fermentation batch. Note that approximately 1 g of T7 RNA polymerase is required to produce 100-150 g of mRNA.

[0097] [Table 7-1]

Table 7-2

Table 7-3

Table 7-4

Table 7-5

Table 7-6

Table 7-7

Table 7-8

Table 7-9

Table 7-10

Table 7-11

Table 7-12

Table 7-13

Table 7-14

Table 7-15

Table 7-16

Table 7-17

Table 7-18

[0098] Equivalence and Scope While several embodiments of the invention have been described and illustrated herein, those skilled in the art can readily envision various other means and / or structures for performing the functions and / or results and / or obtaining one or more advantages described herein, and each such variation and / or modification is deemed to be within the scope of the embodiments of the invention described herein. More generally, those skilled in the art will readily recognize that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the particular application(s) for which the teachings of the invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Thus, the foregoing embodiments are presented by way of example only, and it will be understood that within the scope of the appended claims and equivalents thereto, embodiments of the invention may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. Furthermore, any combination of two or more of such features, systems, articles, materials, kits, and / or methods is within the inventive scope of the present disclosure, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent.

[0099] All definitions defined and used herein are understood to take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0100] All references, patents, and patent applications disclosed herein are hereby incorporated by reference with respect to the subject matter cited, in some cases including the entire document.

[0101] The indefinite articles "a" and "an," as used in the specification and claims, unless clearly indicated to the contrary, should be understood to mean "at least one."

[0102] The term "and / or" as used herein and in the claims should be understood to mean "either or both" of the elements so combined, i.e., elements that are conjunctive in some cases and disjunctive in other cases. Elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so combined. Optionally, other elements may be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to the elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may refer in some embodiments to only A (optionally including elements other than B), in other embodiments to only B (optionally including elements other than A), in yet other embodiments to both A and B (optionally including other elements), and so forth. As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" defined above. For example, when separating items in a list, "or" or "and / or" shall be construed as inclusive, i.e., including not only at least one, but also more than one, and optionally additional items not in the list, of a plurality or list of elements. Only terms expressly indicated to the contrary, such as "only one" or "exactly one," or the term "consisting of," when used in the claims, shall refer to the inclusion of exactly one element of a plurality or list of elements. In general, the term "or" as used herein shall be construed to indicate exclusive alternatives (i.e., "one or the other but not both") only when preceded by a term indicating exclusivity, such as "either," "one," "only one," or "exactly one." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0103] As used in this specification and claims, the phrase "at least one" in reference to a list of one or more elements is understood to mean at least one element selected from any one or more of the elements in that list of elements, but does not necessarily include at least one of each and every element specifically listed in the list of elements, and does not exclude any combination of elements in that list of elements. This definition also recognizes that there may optionally be elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer in some embodiments to at least one, optionally more than one, A, and no B (optionally including elements other than B); in other embodiments to at least one, optionally more than one, B, and no A (optionally including elements other than A); in yet other embodiments to at least one, optionally more than one, A, and at least one, optionally more than one, B (optionally including other elements); etc. Each possibility represents a separate embodiment of the present invention.

[0104] Unless expressly indicated to the contrary, disclosure of numerical values ​​and numerical ranges herein should be understood to include both i) the exact value(s) or range specified, and ii) values ​​that are "around" (about) the specified value(s) or range (e.g., a value or range that falls within a reasonable range (e.g., about 10%)) as would be understood by one of ordinary skill in the art.

[0105] It is also to be understood that, unless expressly stated to the contrary, in any method disclosed herein that includes two or more steps or actions, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are disclosed.

[0106] In the claims and the above specification, transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are all understood to be open-ended, i.e., meaning including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as defined in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

Claims

1. A genetically modified microorganism comprising a genome in which the ompT gene and the lon gene are mutated, disabled, or deleted.

2. 2. The genetically modified microorganism of claim 1, wherein the microorganism does not express a functional form of one or more proteins selected from the group consisting of G6PI, ManA, ManB, ManC, Gmd, Fcl, and KduI.

3. 3. The genetically modified microorganism of claim 1 or 2, wherein the genome comprises a mutation in a gene selected from the group consisting of pgi, manA, manB, manC, gmd, fcl, and kduI.

4. The genetically modified microorganism of any one of claims 1 to 3, wherein the genome comprises a mutation in a promoter operably linked to a gene selected from the group consisting of pgi, manA, manB, manC, gmd, fcl, and kduI.

5. The genetically modified microorganism of any one of claims 1 to 4, wherein the genome does not contain a nucleic acid sequence encoding a carbohydrate metabolism protein selected from the group consisting of G6PI, ManA, ManB, ManC, Gmd, Fcl, and KduI.

6. The genetically modified microorganism of any one of claims 1 to 5, wherein the microorganism does not express functional ManA.

7. The genetically modified microorganism according to any one of claims 1 to 6, wherein the genome comprises a mutation in the manA gene or a promoter operably linked to the manA gene.

8. The genetically modified microorganism according to any one of claims 1 to 7, wherein the genome does not contain a nucleic acid sequence encoding ManA.

9. The genetically modified microorganism according to any one of claims 1 to 8, wherein the genome comprises i) a first nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:23, and ii) a second nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:

25.

10. 10. The genetically modified microorganism of claim 9, wherein the genome further comprises a third nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:

24.

11. The genetically modified microorganism of any one of claims 1 to 10, wherein the microorganism does not exhibit a mucoid phenotype.

12. The genetically modified microorganism according to any one of claims 1 to 11, wherein the microorganism is unable to synthesize mannose.

13. The genetically modified microorganism according to any one of claims 1 to 12, wherein the microorganism is unable to synthesize fucose.

14. i) the genome does not contain a nucleic acid sequence encoding endA; i) the genome does not contain a nucleic acid sequence encoding recA; iii) the EcoK1 restriction system is inactivated; A genetically modified microorganism according to any one of claims 1 to 13.

15. The genetically modified microorganism according to any one of claims 1 to 14, wherein the genotype of the microorganism is ΔendA ΔrecA Δ(mrr-hsdRMS-symE-mcrBC) ΔompT ΔmanA Δlon.

16. The genetically modified microorganism according to any one of claims 1 to 15, wherein the microorganism is E. coli.

17. 17. The genetically modified microorganism of claim 16, wherein the microorganism is derived from E. coli MG1655.

18. 18. The genetically modified microorganism of any one of claims 1 to 17, further comprising a nucleic acid sequence encoding a recombinant protein.

19. 20. The genetically modified microorganism of claim 18, wherein the nucleic acid sequence encoding the recombinant protein is located in the genome of the microorganism.

20. 20. The genetically modified microorganism of claim 19, wherein the nucleic acid sequence encoding the recombinant protein is located on a plasmid.

21. The genetically modified microorganism according to any one of claims 18 to 20, wherein the recombinant protein is an RNA polymerase.

22. 22. The genetically modified microorganism of claim 21, wherein the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase.

23. The RNA polymerase is, relative to a wild-type RNA polymerase, (a) amino acid substitutions at binding site residues for de novo RNA synthesis, and (b) Amino acid modifications that result in increased transcription efficiency The genetically modified microorganism of claim 22 .

24. 24. The genetically modified microorganism of claim 23, wherein the amino acid modification is an amino acid substitution at position 47 relative to the wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO:

34.

25. 25. The genetically modified microorganism of claim 24, wherein the amino acid substitution at position 47 is G47A.

26. 26. The genetically modified microorganism of any one of claims 23 to 25, wherein the amino acid modification comprises an additional C-terminal amino acid relative to the wild-type RNA polymerase.

27. 27. The genetically modified microorganism of claim 26, wherein the additional C-terminal amino acid is glycine.

28. The genetically modified microorganism of any one of claims 23 to 27, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:

41.

29. The RNA polymerase is capable of activating a wild-type RNA polymerase. (a) an amino acid substitution at position 350, and / or (b) an amino acid substitution at position 351 wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO:

34. The genetically modified microorganism according to any one of claims 21 to 27.

30. 30. The genetically modified microorganism of claim 29, wherein the amino acid substitution at position 350 is E350W.

31. 30. The genetically modified microorganism of claim 29, wherein the amino acid substitution at position 351 is D351V.

32. 30. The genetically modified microorganism of claim 29, wherein the amino acid substitution at position 350 is E350W and the amino acid substitution at position 351 is D351V.

33. The genetically modified microorganism of any one of claims 29 to 32, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:

42.

34. The genetically modified microorganism of any one of claims 23 or 29 to 32, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:

43.

35. 1. A method for producing a polypeptide or protein, comprising: i) introducing a nucleic acid molecule comprising a sequence encoding a polypeptide or protein into a genetically modified microorganism according to any one of claims 1 to 17; ii) culturing said genetically modified organism under conditions suitable for expression of said polypeptide or protein; iii) isolating said polypeptide or protein; The method comprising:

36. 1. A method for producing a polypeptide or protein, comprising: i) culturing a genetically modified organism according to any one of claims 18 to 34 under conditions suitable for the expression of said polypeptide or protein; ii) isolating said polypeptide or protein; The method comprising:

37. 37. The method of claim 35 or 36, wherein the polypeptide or protein is an RNA polymerase.

38. 38. The method of claim 37, wherein the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, or K11 RNA polymerase.

39. The RNA polymerase is, relative to a wild-type RNA polymerase, (a) amino acid substitutions at binding site residues for de novo RNA synthesis, and (b) Amino acid modifications that result in increased transcription efficiency 39. The method of claim 38, comprising:

40. 40. The method of claim 39, wherein the amino acid modification is an amino acid substitution at position 47 relative to the wild-type RNA polymerase, wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO:

34.

41. 41. The method of claim 40, wherein the amino acid substitution at position 47 is G47A.

42. 42. The method of any one of claims 39 to 41, wherein the amino acid modifications comprise an additional C-terminal amino acid relative to the wild-type RNA polymerase.

43. 43. The method of claim 42, wherein the additional C-terminal amino acid is glycine.

44. The method of any one of claims 40 to 43, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:

41.

45. The RNA polymerase is capable of activating a wild-type RNA polymerase. (a) an amino acid substitution at position 350, and (b) an amino acid substitution at position 351 wherein the wild-type RNA polymerase comprises the amino acid sequence of SEQ ID NO:

34.

44. The method according to any one of claims 37 to 43.

46. 46. ​​The method of claim 45, wherein the amino acid substitution at position 350 is E350W.

47. 46. ​​The method of claim 45, wherein the amino acid substitution at position 351 is D351V.

48. 46. ​​The method of claim 45, wherein the amino acid substitution at position 350 is E350W and the amino acid substitution at position 351 is D351V.

49. The method of any one of claims 45 to 48, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:

42.

50. 49. The method of any one of claims 39 or 45-48, wherein the RNA polymerase comprises the amino acid sequence of SEQ ID NO:43.